- Report
- September 2024
- 82 Pages
Japan
From €3185EUR$3,500USD£2,731GBP
- Report
- August 2024
- 80 Pages
Japan
From €3185EUR$3,500USD£2,731GBP
- Report
- April 2024
- 190 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- October 2023
- 189 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- October 2023
- 190 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- April 2023
- 115 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- August 2022
- 111 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- June 2021
Global
From €13647EUR$14,995USD£11,699GBP
- Report
- October 2019
- 128 Pages
Global
From €13647EUR$14,995USD£11,699GBP
- Report
- April 2022
- 188 Pages
Global
From €3276EUR$3,600USD£2,809GBP
- Report
- April 2023
- 326 Pages
Global
From €3276EUR$3,600USD£2,809GBP
- Report
- January 2024
- 113 Pages
United States
€3185EUR$3,500USD£2,731GBP
- Report
- March 2023
- 30 Pages
Global
€11149EUR$12,250USD£9,558GBP
- Report
- August 2018
- 21 Pages
Global
From €9101EUR$10,000USD£7,802GBP
- Report
- April 2018
United States
From €7276EUR$7,995USD£6,238GBP
- Report
- August 2024
- 82 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- February 2024
- 85 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- January 2024
- 87 Pages
Global
From €3500EUR$4,120USD£3,106GBP

Infliximab is a monoclonal antibody used to treat a variety of immune disorders, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. It works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Infliximab is administered intravenously and is usually given in combination with other medications. It is also used to treat certain types of eye inflammation and to prevent organ rejection in transplant patients.
Infliximab is a biologic drug, meaning it is derived from living cells. It is produced by a number of pharmaceutical companies, including Merck, Pfizer, and Janssen. It is available in both brand-name and generic forms.
The companies in the Infliximab market include Merck, Pfizer, Janssen, Celltrion, Hospira, and Sandoz. Show Less Read more